Humoral and cell mediated immune response to SARS-CoV-2 vaccination in patients with immune-mediated diseases
Authors:
Open Access
- 18 May 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1813924
Abstract
Background: Vaccination against SARS-CoV-2 induces an immune response that is protective against severe disease in healthy populations. However, humoral and cellular immune responses in individuals with immune-mediated diseases receiving immunosuppressive medications are not well understood. Methods: We conducted a single-center, prospective observational cohort study of pediatric and adult patients with vasculitis, glomerular disease, or other immune-mediated diseases. Antibody response assessed by viral neutralization and, in a subset, cellular immunity to SARS-CoV-2 vaccination were assessed before and at time points following initial and booster vaccination. Results: Between March 2021 and June 2022, 80 individuals with immune-mediated diseases and 12 healthy controls were enrolled and followed for a median of 11.97 months (IQR 7.64, 14.05). Following vaccination, the median percent angiotensin-converting enzyme 2 (ACE2) neutralization at V1 (1–3 months post vaccination) for patients in the immune-mediated disease cohort and healthy controls were 46.9% (IQR 0.65, 95.6) and 95.9% (IQR 94.6, 96.5), respectively. Of 26 individuals with anti-CD20 therapy exposure or laboratory evidence of B cell depletion at time of vaccination, only 11.9% had protective neutralization titers at V1. After adjustment for age, sex, BMI, race, vaccine type, and number of comorbidities, anti-CD20 exposure at time of initial vaccination remained significantly associated with a lower odds of ACE2 neutralization ≥30% at V1. The median T-ELISpot counts (RBD) at V1 for patients with immune-mediated diseases and healthy controls were comparable (16 [IQR 12, 37] and 16 [IQR 4.5, 23], respectively). Conclusions: Vaccination against SARS-CoV-2 during treatment with anti-CD20 antibody therapy was associated with impaired humoral immunity, but T cell responses were qualitatively preserved despite immunosuppressant exposure.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (K23AI159073)
- National Institute of Diabetes and Digestive and Kidney Diseases
This publication has 26 references indexed in Scilit:
- COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapiesJournal of Translational Autoimmunity, 2022
- Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapyJournal of Autoimmunity, 2022
- Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patientsCellular Immunology, 2022
- Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21The Lancet, 2022
- SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to OmicronCell, 2022
- SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected peopleCell Reports, 2022
- Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapyEBioMedicine, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Systematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney DiseaseKidney International Reports, 2021
- An improved approximation to the precision of fixed effects from restricted maximum likelihoodComputational Statistics & Data Analysis, 2009